Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer: Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial

Oncology

Volumn 71, Issue 1-2, 2007, Pages 40-48

  Borget, Isabelle ^a   Aupérin, Anne ^a   Pignon, Jean Pierre ^a   Abbas, Moncef ^a   Bouché, Olivier ^b   Mousseau, Mireille ^c   Raoul, Jean Luc ^d   Bedenne, Laurent ^e   Cassan, Philippe ^f   Clavero Fabri, Marie Christine ^g   Stremsdoerfer, Noël ^h   Nasca, Salvador ⁱ   Queuniet, Anne Marie ^h   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f CHG Vichy   (France)

^g CMC Bligny   (France)

^h CH Bourgoin Jallieu ^*  (France)

ⁱ INSTITUT JEAN GODINOT   (France)

Author keywords

Cost effectiveness analysis; Metastatic colorectal cancer; Raltitrexed; Randomized trial

Indexed keywords

CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL CHARGE; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FRANCE; HEALTH CARE COSTS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; SURVIVAL RATE; THIOPHENES; TREATMENT OUTCOME;

EID: 34247172544     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100448     Document Type: Article

References (33)

1. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488.
2. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-535.
3. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, Sjoden PO: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-274.
4. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
5. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-3728.
6. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 1996;7:961-965.
7. Moutney LSH, Harris J: Colorectal cancer. Health care needs assessment. 1993.
8. Industry AotBP: The value of medicines: bowel and breast cancer. ABPI, 1997.
9. Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T: Cost of colorectal cancer in France in 1999. Gastroenterol Clin Biol 2003;27:22-27.
10. Drummond M: Evaluation of health technology: economic issues for health policy and policy issues for economic appraisal. Soc Sci Med 1994;38:1593-1600.
11. Ross P, Heron J, Cunningham D: Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996;32A(suppl 5):S13-S17.
12. Kerr D, O'Connor K: An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. J Drug Assess 1999;2:295-304
13. Hale JP, Cohen DR, Maughan TS, Stephens RJ: Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer 2002;86:1684-1690.
14. Groener MG, van Ineveld BM, Byttebier G, van Hout BA, Rutten FF: An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999;10:283-288.
15. Remonnay R, Devaux Y, Chauvin F, Dubost E, Carrere MO: Economic evaluation of antineoplasic chemotherapy administered at home or in hospitals. Int J Technol Assess Health Care 2002;18:508-519.
16. Aligon A C-RL, Renaud T: Evaluation du coût de la prise en charge globale en hospitalisation à domicile; in IRDES (ed), 2003, p 268.
17. UCANSS: Nomenclature Générale des Actes Professionnels; in Edit. Paris, 2000.
18. (CNAMTS) CCNdAMdTS: Transports: Rappel des dispositions actuelles concernant la prise en charge des frais de transport et précisions sur le relevé de conclusions signé le 10/10/1996 entre les 5 organisations de transporteurs et les 3 caisses nationales d'assurance maladie. 1996.
19. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-1563.
20. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998;16:2943-2952.
21. Pazdur R, VM: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer: results of a randomised, multicenter, North American trial; in Oncol PASC (ed), 1997, p 228a.
22. Kohne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dorken B: Raltitrexed (Tomudex): An alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998;77:973-977.
23. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
24. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
25. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
26. Taieb J, Boige V, Ducreux M: The new chemotherapy of colorectal cancers. Presse Méd 2002;31:132-138.
27. Aparicio J, Vicent JM, Maestu I, Bosch C, Galan A, Busquier I, Llorca C, Garcera S, Campos JM, Lopez-Tendero P, Balcells M: First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study. Oncology 2005;68:58-63.
28. Feliu J, Castanon C, Salud A, Mel JR, Escudero P, Pelegrin A, Lopez-Gomez L, Ruiz M, Gonzalez E, Juarez F, Lizon J, Castro J, Gonzalez-Baron M: Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005;93:1230-1235.
29. Vyzula R, Kocakova I, Demlova R, Kiss I, Dusek L, Jarkovsky J: Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Neoplasma 2006;53:119-127.
30. Santini D, Massacesi C, D'Angelillo RM, Marcucci F, Campisi C, Vincenzi B, Pilone A, Bianco V, Bonsignori M, Tonini G: Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol 2004;21:59-66.
31. Locher C, Auperin A, Boige V, Alzieu L, Pignon JP, Abbas M, Ducreux M: Assessment of the cost of first-line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial. Gastroenterol Clin Biol 2001;25:749-754.
32. Coyle D, Davies L, Drummond MF: Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials. Int J Technol Assess Health Care 1998;14:135-144.
33. Brown M, GH, Harrell F, et al : Integrating economic analysis into cancer clinical trials: the National Cancer-Institute-American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monogr 1998;24:1-28.